Newsbot

Gold and Silver Storm to Records as Fed Hit With Subpoenas

Gold and silver climbed to records in a broad-based metals rally as the US Justice Department threatened the Federal Reserve with a criminal indictment, reviving concerns over the central bank’s independence.

Zymeworks Outlines Strategic Priorities and Outlook for 2026

VANCOUVER, British Columbia, Jan. 11, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics, today outlined its strategic priorities and key milestones for 2026. Following a year of significant clinical, operational and financial progress, Zymeworks is focused on executing a long-term strategy designed to maximize value creation for patient...

China’s PE Trailblazer Hopu Faces Doubts on Returns, Succession

As Fang Fengleis Hopu Investment Management seeks $1.5 billion to $2 billion for a new flagship fund, longtime backers including Temasek and CIC are reconsidering whether to invest after years of middling returns and leadership churn.

Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference: Pivot to Growth Strategy Delivering Growth and Transforming through Innovation

Richard Francis, Tevas President and CEO, will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 8:15 A.M. Pacific Time (11:15 A.M. Eastern Time) Richard Francis, Tevas President and CEO, will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 8:15 A.M. Pacific Time (11:15 A.M. Eastern Time)

Royalty Pharma and Teva Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo

NEW YORK and PARSIPPANY, N.J., Jan. 11, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced a funding agreement of up to $500 million to accelerate the clinical development of Teva’s anti-IL-15 antibody, TEV-408. IL-15 is a key cytokine involved in multiple immune-mediated disease pathways. Emerging Phase 1b data from the ongoing TEV-‘408 vitiligo study provides prel...

Record Revenue And Backlog Volatility Might Change The Case For Investing In MasTec (MTZ)

In recent trading, MasTec reported record third-quarter revenue and a larger backlog, yet management cautioned that permitting delays and shifting customer spending can cause significant quarter-to-quarter swings in margins and cash flow.This mix of strong activity and operational uncertainty highlights how timing issues in major infrastructure projects can materially influence MasTec’s near-term financial profile.Next, we’ll examine how these permitting and spending-related margin swings...

Teva and Royalty Pharma Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo

PARSIPPANY, N.J., and NEW YORK, Jan. 11, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Royalty Pharma plc (Nasdaq: RPRX), today announced a funding agreement of up to $500 million to accelerate the clinical development of Teva’s anti-IL-15 antibody, TEV-’408. IL-15 is a key cytokine involved in multiple immune-mediated disease pathways. Emerging Phase 1b data from the ongoing TEV-‘408 vitiligo study provides pr...

ROUNDUP 2: Wadephul auf Island - Themen Grönland und Arktis-Sicherheit

REYKJAVIK (dpa-AFX) - Außenminister Johann Wadephul macht auf seinem Flug in die USA einen Zwischenstopp auf Island. Auf der nur knapp 300 Kilometer südöstlich von Grönland liegenden Insel kam der CDU-Politiker mit seiner Kollegin Thorgerdur Katrín G...